Abbott Laboratories (ABT)

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

We take a look at three top-rated companies that have raised their dividends without interruption for decades.

Abbott’s business and dividend story remain intact even as the stock trades near 52‑week lows.

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

ABBOTT PARK, Ill. , April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™...

ABBOTT PARK, Ill. , April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation...

Abbott Labs is a balance of income and growth.

ABBOTT PARK, Ill. , April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements...

Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.

Abbott Laboratories (ABT) has reported first-quarter financial results that narrowly beat Wall Street’s ...